Welcome to our dedicated page for Dexcom SEC filings (Ticker: DXCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dexcom鈥檚 CGM sensors may be tiny, but the disclosures behind them are anything but. Each annual report details sensor accuracy studies, reimbursement progress, and manufacturing scale that drive the company鈥檚 growth. If you have ever searched for the G7 margin breakout or the cost of disposable sensors, you know the data is buried deep inside SEC exhibits.
Stock Titan鈥檚 AI engine makes those details surface quickly. Our platform delivers Dexcom SEC filings explained simply and tags the passages investors care about鈥攚hether it is an 8-K announcing an FDA clearance or the footnote that spells out international revenue. Get instant alerts for Dexcom Form 4 insider transactions real-time and track every share purchase or sale by executives. For deeper diligence, compare the Dexcom quarterly earnings report 10-Q filing against the prior period with side-by-side AI summaries.
Here is what you can explore in one place:
- Dexcom annual report 10-K simplified 鈥� sensor unit economics, R&D spending, and risk factors distilled into plain English.
- Dexcom 8-K material events explained 鈥� from product recalls to strategic partnerships.
- Dexcom executive stock transactions Form 4 鈥� pattern recognition on option exercises and sales.
- Dexcom proxy statement executive compensation 鈥� understand incentive structures tied to new product launches.
Whether you need a quick Dexcom earnings report filing analysis before the call or are understanding Dexcom SEC documents with AI for a full valuation model, Stock Titan provides comprehensive coverage and real-time updates. No more hunting through EDGAR鈥攃ritical insights on Dexcom insider trading Form 4 transactions land in your dashboard the moment they post.
Baiya International Group Inc. (BIYA) filed a Form 6-K announcing a board change effective 21 July 2025.
- Director and Audit Committee chair Zicen Liao resigned; the company states the departure involved no disagreements on operations, policies or practices.
- The remaining directors appointed Yankun Wang to fill the vacancy. She becomes director, Audit Committee chair, and a member of both the compensation and nominating committees.
- Wang has 10+ years of HR and administrative experience, most recently as HR & Administration Manager at Jinke Yulv Technology (Mar 2023鈥損resent) and previously Deputy Director of Administration at Sichuan Jiaotou Tianfu AG真人官方 Estate (2019鈥�2023). She holds a nationally accredited Economics Professional Qualification and a B.A. in marketing from Sichuan Normal University.
The filing contains no financial results, strategic initiatives, or transaction details; its scope is limited to the governance change.
LSB Industries, Inc. (NYSE: LXU) filed a Form 8-K to furnish Item 2.02 information. The company released its second-quarter 2025 financial results via an attached press release (Exhibit 99.1) dated July 29, 2025 and scheduled a live webcast conference call for July 30, 2025 at 10:00 a.m. ET / 9:00 a.m. CT to review the quarter. No financial figures are included in the filing itself. All information in Item 2.02 is deemed 鈥渇urnished,鈥� not 鈥渇iled,鈥� and is therefore excluded from Exchange Act liability and from incorporation by reference in future SEC filings unless specifically referenced.
DexCom, Inc. (DXCM) Form 144 filing discloses a proposed sale of 1,466 common shares by shareholder Sadie Stern through Morgan Stanley Smith Barney. The shares, valued at $130,459, are expected to be sold on or about 28 Jul 2025 on the NASDAQ. They represent roughly 0.0004 % of DexCom鈥檚 392.1 million shares outstanding, implying minimal market impact.
The shares were acquired as restricted stock on 19 Nov 2023. In the last three months, the same holder completed four sales totaling 7,650 shares for $651,016 in gross proceeds, indicating an ongoing liquidation pattern. No other insiders or financial metrics are disclosed.
The filer affirms awareness of no undisclosed adverse information and notes potential reliance on a Rule 10b5-1 trading plan. Aside from insider-sale data, the filing contains no operational or earnings updates.
Amaze Holdings, Inc. (NYSE American: AMZE), formerly Fresh Vine Wine, filed an 8-K dated 11 July 2025 to disclose a new consulting agreement and related unregistered share issuance.
- Consulting Agreement: Signed 11 July 2025 with DNA Holdings Venture Inc. (Puerto Rico) for a 12-month term, auto-renewable for another 12 months unless cancelled on 30-days notice.
- Scope of Services: Crypto strategy & token architecture, e-commerce/Web3 integration, cross-border currency solutions, credibility/visibility support and market-making for the Company鈥檚 planned Token Generation Event.
- Consideration: Company issued 100,000 common shares to the Consultant. No cash payment disclosed.
- Unregistered Securities: Shares issued under Section 4(a)(2) and/or Rule 506(b) of Regulation D, relying on the private-offering exemption.
- Reg FD: A press release announcing the agreement was furnished as Exhibit 99.1 on 15 July 2025.
- Exhibits: 10.1 (Consulting Agreement), 99.1 (Press Release), 104 (Cover Page iXBRL file).
No financial performance metrics were provided in this filing. The transaction introduces crypto-related strategic initiatives while creating modest share dilution.
Ciena Corporation (CIEN) has filed a Form 144 indicating that an insider plans to sell 734 common shares through Morgan Stanley Smith Barney LLC on or about 15 July 2025 via the NYSE. The proposed transaction is valued at $60,606.38 and represents less than 0.001 % of CIEN鈥檚 141,367,218 shares outstanding. The shares were acquired as restricted stock on 20 June 2025. No other insider sales were reported in the last three months, and the filing contains no additional financial or operational disclosures.
Bank of Montreal (BMO) is marketing Auto-Callable Market Linked Securities with Contingent Coupons, Memory Feature and Contingent Downside Principal at Risk, linked to the worst performer among Apple Inc., Broadcom Inc. and McDonald鈥檚 Corporation. The $1,000-denominated notes price on 11 Jul 2025, settle on 16 Jul 2025 and mature on 14 Jul 2028 (3-year tenor unless called earlier).
Income profile: Investors receive a quarterly contingent coupon of at least 21.25 % p.a. (5.3125 % per quarter) provided the worst-performing underlier is 鈮� 80 % of its starting value on the relevant calculation day. The 鈥渕emory鈥� feature adds any missed coupons once the threshold is next met.
Auto-call: From Oct 2025 to Apr 2028, if the worst performer is 鈮� its starting value on a calculation day, the notes are automatically called at par plus the coupon, ending the investment early and creating reinvestment risk.
Principal repayment: If not previously called, at maturity holders receive: (i) 100 % of face if the worst performer is 鈮� 70 % of its starting value; or (ii) par 脳 performance factor of the worst performer if it is < 70 %. Investors therefore face full downside exposure below the 30 % buffer and could lose all principal.
Key structural terms: Starting values set on pricing date; coupon threshold 80 %; downside threshold 70 %; estimated initial value disclosed as $966.40 (96.64 % of face) and will not be less than $916.00. Agent discount up to 2.325 %; additional dealer fees up to 0.30 %.
Risks highlighted: conditional coupons (may receive none), potential loss of > 30 % of principal, reliance on worst performer, credit risk to BMO, illiquid secondary market, pricing transparency, and uncertain U.S. tax treatment. The notes are unsecured, not FDIC-insured and will not list on any exchange.
DexCom, Inc. (DXCM) 鈥� Form 4 insider transaction
EVP & Chief HR Officer Sadie Stern reported the sale of 1,466 common shares on 26-Jun-2025 at an average price of $85.06, generating gross proceeds of roughly $125,000. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted 20-Feb-2025, signalling that timing was automated rather than discretionary.
Following the sale, Stern鈥檚 beneficial ownership stands at 108,155 shares, of which 74,450 are unvested RSUs scheduled to vest between 2026 and 2028. The reported sale represents ~1.4% of her post-transaction holdings, leaving her overall exposure to DexCom equity largely intact.
No derivative transactions, option exercises, or additional sales were disclosed, and there is no indication of strategic changes or financial performance data within this filing.
FAQ
What is the current stock price of Dexcom (DXCM)?
What is the market cap of Dexcom (DXCM)?
What is the primary focus of Dexcom Inc?
How does Dexcom Inc integrate its technology with insulin delivery systems?
Who are the primary customers of Dexcom Inc?
What differentiates Dexcom Inc from other diabetes care companies?
How does Dexcom Inc generate revenue?
What is the competitive landscape for Dexcom Inc in the medical device industry?
